News
MRNA
143.56
+0.96%
1.37
US Government Offers $75M Support For Lipid Systems Expansion Used In mRNA COVID-19 Vaccines
Benzinga · 1d ago
Moderna (MRNA) Gains As Market Dips: What You Should Know
In the latest trading session, Moderna (MRNA) closed at $145.36, marking a +0.76% move from the previous day.
Zacks · 1d ago
Insider Sell: Moderna
MT Newswires · 1d ago
Pfizer booster improved to fight omicron, as hospitalizations rise to 3-month high
Pfizer Inc. and partner BioNTech SE said the update to their COVID-19 booster shot showed a "high immune response" against the omicron variant, in time for an FDA meeting and as the daily average of COVID-19-related hospitalizations rose to a 3-month high.
marketwatch.com · 2d ago
What Are Whales Doing With Moderna
A whale with a lot of money to spend has taken a noticeably bearish stance on Moderna. Looking at options history for Moderna (NASDAQ:MRNA) we detected 13 strange trades.
Benzinga · 2d ago
Pfizer's (PFE) Omicron-Based COVID Shot Betters Immune Response
Pfizer (PFE) and partner BioNTech's (BNTX) Omicron-specific COVID vaccine candidates achieves a higher immune response against the variant in a phase II/III study.
Zacks · 2d ago
Clover COVID vaccine's booster shot shows response against Omicron variants
Clover Biopharmaceuticals said that a third dose of its COVID-19 vaccine showed neutralizing antibody levels against Omicron variants in a trial. Clover noted that it created its COVID-19 vaccine candidate by
Seekingalpha · 2d ago
FDA Panel Will Weigh In on Covid Boosters for This Fall. What’s at Stake.
The early case for the mRNA-based Covid-19 vaccines was that the adaptability of the technology meant they could be updated to match the virus as it evolved.
Barrons.com · 2d ago
Pfizer says updated COVID-19 booster can provide more protection against super-contagious omicron
Pfizer and BioNTech say in update that changing the COVID-19 vaccine to better target the omicron variant is safe and effective.
marketwatch.com · 3d ago
Pfizer’s Omicron-Targeting Covid-19 Vaccines Generate Stronger Immune Response
One shot that was tested targeted Omicron specifically, while another was modified to work against the strain and the original virus.
The Wall Street Journal · 4d ago
Pfizer/BioNTech say Omicron-based COVID shots improve response vs that variant
Pfizer/BioNTech say Omicron-based COVID shots improve response vs that variant
reuters.com · 4d ago
Is Moderna Stock A Buy As The Covid Battle With Pfizer Heats Up?
Is Moderna stock a buy after the FDA authorized its Covid vaccine for children as young as 6 months old? Is MRNA stock a buy right now?
Investor's Business Daily · 4d ago
Moderna Inc. stock rises Friday, still underperforms market
marketwatch.com · 4d ago
Bristol-Myers MS drug linked to better COVID response with mRNA shots
Bristol Myers Squibb (NYSE:BMY) said on Friday that the patients taking its multiple sclerosis therapy drug Zeposia (ozanimod) were more likely to develop COVID-19 antibodies to mRNA vaccines compared to
Seekingalpha · 4d ago
BRIEF-CDC Recommends Moderna Covid-19 Vaccine For Children And Adolescents
reuters.com · 5d ago
Moderna Covid Shot for Children, Teens Gets CDC Support
Bloomberg · 5d ago
CDC Recommends Moderna’s Covid-19 Vaccine for Kids 6 to 17 Years
The CDC recommended use of Moderna’s Covid-19 vaccine in children 6 to 17 years, the final step in allowing the shots to become widely available.
The Wall Street Journal · 5d ago
CDC panel backs Moderna vaccine for children aged 6 to 17, and study finds vaccines saved about 20 million lives in their first year
A panel of advisers to the Centers for Disease Control and Prevention voted unanimously Thursday to recommend Moderna's COVID vaccine for children and adolescents aged 6 to 17.
marketwatch.com · 5d ago
Pharma Stock Roundup: FDA OK's Expanded Use of ABBV, MRK, NVS Drugs, Other Updates
The FDA approves expanded use of AbbVie's (ABBV) Skyrizi, Merck's (MRK) Vaxneuvance vaccine and Novartis's (NVS) cancer combination drugs, Tafinlar (dabrafenib) + Mekinist (trametinib).
Zacks · 5d ago
More
Webull provides a variety of real-time MRNA stock news. You can receive the latest news about Moderna through multiple platforms. This information may help you make smarter investment decisions.
About MRNA
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, and systemic intracellular therapeutics. The Company develops technologies that enable the development of mRNA medicines.